Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis

摘要: The current guidelines and recent clinical research in the management of Pseudomonas aeruginosa respiratory infections cystic fibrosis (CF) are reviewed. Areas where further is required will also be highlighted. P. a key pathogen CF. Inhaled tobramycin or colistin recommended for early eradication to prevent establishment chronic infection. Other antibiotic options currently being investigated. long-term success strategies now assessed. use inhaled antibiotics P. infection an area active investigation. Acute pulmonary exacerbations still major cause morbidity mortality. Guidelines continue recommend combination intravenous therapy but clarify advantage this approach. Multidrug resistance common potentially more effective antipseudomonal may soon become available. The CF remains challenging area, especially setting multidrug resistance. role continues expanded. Further areas acute identify those treatments that optimize long-term, benefits.